INNATE PHARMA SA (IDD.DE) Stock Fundamental Analysis

FRA:IDD • FR0010331421

1.506 EUR
+0.02 (+1.21%)
Last: Jan 28, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

2

Overall IDD gets a fundamental rating of 2 out of 10. We evaluated IDD against 78 industry peers in the Biotechnology industry. IDD has a bad profitability rating. Also its financial health evaluation is rather negative. IDD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year IDD has reported negative net income.
  • IDD had a negative operating cash flow in the past year.
  • IDD had negative earnings in each of the past 5 years.
  • IDD had a negative operating cash flow in each of the past 5 years.
IDD.DE Yearly Net Income VS EBIT VS OCF VS FCFIDD.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • IDD's Return On Assets of -49.55% is on the low side compared to the rest of the industry. IDD is outperformed by 64.71% of its industry peers.
  • The Return On Equity of IDD (-895.24%) is worse than 68.24% of its industry peers.
Industry RankSector Rank
ROA -49.55%
ROE -895.24%
ROIC N/A
ROA(3y)-25.54%
ROA(5y)-23.43%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
IDD.DE Yearly ROA, ROE, ROICIDD.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400 -500

1.3 Margins

  • IDD's Gross Margin of 49.52% is in line compared to the rest of the industry. IDD outperforms 47.06% of its industry peers.
  • In the last couple of years the Gross Margin of IDD has declined.
  • The Profit Margin and Operating Margin are not available for IDD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 49.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.49%
GM growth 5Y-4.49%
IDD.DE Yearly Profit, Operating, Gross MarginsIDD.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • IDD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, IDD has more shares outstanding
  • Compared to 5 years ago, IDD has more shares outstanding
  • Compared to 1 year ago, IDD has an improved debt to assets ratio.
IDD.DE Yearly Shares OutstandingIDD.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IDD.DE Yearly Total Debt VS Total AssetsIDD.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • Based on the Altman-Z score of -6.44, we must say that IDD is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -6.44, IDD is doing worse than 70.59% of the companies in the same industry.
  • A Debt/Equity ratio of 3.52 is on the high side and indicates that IDD has dependencies on debt financing.
  • IDD has a worse Debt to Equity ratio (3.52) than 63.53% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.52
Debt/FCF N/A
Altman-Z -6.44
ROIC/WACCN/A
WACC6.84%
IDD.DE Yearly LT Debt VS Equity VS FCFIDD.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 2.21 indicates that IDD has no problem at all paying its short term obligations.
  • The Current ratio of IDD (2.21) is comparable to the rest of the industry.
  • IDD has a Quick Ratio of 2.21. This indicates that IDD is financially healthy and has no problem in meeting its short term obligations.
  • IDD has a Quick ratio of 2.21. This is comparable to the rest of the industry: IDD outperforms 51.76% of its industry peers.
Industry RankSector Rank
Current Ratio 2.21
Quick Ratio 2.21
IDD.DE Yearly Current Assets VS Current LiabilitesIDD.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The earnings per share for IDD have decreased strongly by -30.42% in the last year.
  • IDD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -75.86%.
  • Measured over the past years, IDD shows a very negative growth in Revenue. The Revenue has been decreasing by -28.80% on average per year.
EPS 1Y (TTM)-30.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.82%
Revenue 1Y (TTM)-75.86%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-79.85%

3.2 Future

  • The Earnings Per Share is expected to decrease by -19.15% on average over the next years. This is quite bad
  • Based on estimates for the next years, IDD will show a very strong growth in Revenue. The Revenue will grow by 38.93% on average per year.
EPS Next Y-35.8%
EPS Next 2Y-10.55%
EPS Next 3Y-19.15%
EPS Next 5YN/A
Revenue Next Year-26.21%
Revenue Next 2Y3.05%
Revenue Next 3Y2.41%
Revenue Next 5Y38.93%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IDD.DE Yearly Revenue VS EstimatesIDD.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
IDD.DE Yearly EPS VS EstimatesIDD.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • IDD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IDD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IDD.DE Price Earnings VS Forward Price EarningsIDD.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IDD.DE Per share dataIDD.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

  • A cheap valuation may be justified as IDD's earnings are expected to decrease with -19.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.55%
EPS Next 3Y-19.15%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for IDD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INNATE PHARMA SA

FRA:IDD (1/28/2026, 7:00:00 PM)

1.506

+0.02 (+1.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-26
Inst Owners9.46%
Inst Owner ChangeN/A
Ins Owners0.92%
Ins Owner ChangeN/A
Market Cap141.11M
Revenue(TTM)6.00M
Net Income(TTM)-46.05M
Analysts80
Price Target5.58 (270.52%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-2.23%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 23.52
P/FCF N/A
P/OCF N/A
P/B 27.43
P/tB 27.43
EV/EBITDA N/A
EPS(TTM)-0.55
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0.06
BVpS0.05
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.55%
ROE -895.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 49.52%
FCFM N/A
ROA(3y)-25.54%
ROA(5y)-23.43%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.49%
GM growth 5Y-4.49%
F-Score2
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 3.52
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.84%
Cap/Sales 2.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.21
Quick Ratio 2.21
Altman-Z -6.44
F-Score2
WACC6.84%
ROIC/WACCN/A
Cap/Depr(3y)22.77%
Cap/Depr(5y)23.45%
Cap/Sales(3y)3.3%
Cap/Sales(5y)8.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.82%
EPS Next Y-35.8%
EPS Next 2Y-10.55%
EPS Next 3Y-19.15%
EPS Next 5YN/A
Revenue 1Y (TTM)-75.86%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-79.85%
Revenue Next Year-26.21%
Revenue Next 2Y3.05%
Revenue Next 3Y2.41%
Revenue Next 5Y38.93%
EBIT growth 1Y-31.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.86%
EBIT Next 3Y68.81%
EBIT Next 5YN/A
FCF growth 1Y-27.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.01%
OCF growth 3YN/A
OCF growth 5YN/A

INNATE PHARMA SA / IDD.DE FAQ

Can you provide the ChartMill fundamental rating for INNATE PHARMA SA?

ChartMill assigns a fundamental rating of 2 / 10 to IDD.DE.


Can you provide the valuation status for INNATE PHARMA SA?

ChartMill assigns a valuation rating of 0 / 10 to INNATE PHARMA SA (IDD.DE). This can be considered as Overvalued.


How profitable is INNATE PHARMA SA (IDD.DE) stock?

INNATE PHARMA SA (IDD.DE) has a profitability rating of 0 / 10.


Can you provide the financial health for IDD stock?

The financial health rating of INNATE PHARMA SA (IDD.DE) is 3 / 10.